HTLV-1 infection promotes excessive T cell activation and transformation into adult T cell leukemia/lymphoma.
Infectious disease
Leukemias
MHC class 2
T cells
Virology
Journal
The Journal of clinical investigation
ISSN: 1558-8238
Titre abrégé: J Clin Invest
Pays: United States
ID NLM: 7802877
Informations de publication
Date de publication:
15 12 2021
15 12 2021
Historique:
received:
12
04
2021
accepted:
27
10
2021
entrez:
15
12
2021
pubmed:
16
12
2021
medline:
7
1
2022
Statut:
ppublish
Résumé
Human T cell leukemia virus type 1 (HTLV-1) mainly infects CD4+ T cells and induces chronic, persistent infection in infected individuals, with some developing adult T cell leukemia/lymphoma (ATL). HTLV-1 alters cellular differentiation, activation, and survival; however, it is unknown whether and how these changes contribute to the malignant transformation of infected cells. In this study, we used single-cell RNA-sequencing and T cell receptor-sequencing to investigate the differentiation and HTLV-1-mediated transformation of T cells. We analyzed 87,742 PBMCs from 12 infected and 3 uninfected individuals. Using multiple independent bioinformatics methods, we demonstrated the seamless transition of naive T cells into activated T cells, whereby HTLV-1-infected cells in an activated state further transformed into ATL cells, which are characterized as clonally expanded, highly activated T cells. Notably, the greater the activation state of ATL cells, the more they acquire Treg signatures. Intriguingly, the expression of HLA class II genes in HTLV-1-infected cells was uniquely induced by the viral protein Tax and further upregulated in ATL cells. Functional assays revealed that HTLV-1-infected cells upregulated HLA class II molecules and acted as tolerogenic antigen-presenting cells to induce anergy of antigen-specific T cells. In conclusion, our study revealed the in vivo mechanisms of HTLV-1-mediated transformation and immune escape at the single-cell level.
Identifiants
pubmed: 34907908
pii: 150472
doi: 10.1172/JCI150472
pmc: PMC8670839
doi:
pii:
Substances chimiques
Gene Products, tax
0
HLA Antigens
0
tax protein, Human T-lymphotrophic virus 1
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Medical Research Council
ID : MR/S000208/1
Pays : United Kingdom
Références
Immunology. 1995 Feb;84(2):193-201
pubmed: 7750994
Clin Cancer Res. 2014 Jun 1;20(11):2851-61
pubmed: 24727323
Blood. 2000 Feb 15;95(4):1386-92
pubmed: 10666215
Eur J Immunol. 2004 Dec;34(12):3379-88
pubmed: 15517606
Nat Commun. 2020 Mar 5;11(1):1201
pubmed: 32139671
Retrovirology. 2012 May 30;9:46
pubmed: 22647666
BMC Genomics. 2018 Jun 19;19(1):477
pubmed: 29914354
Br J Haematol. 1991 Nov;79(3):428-37
pubmed: 1751370
Blood. 2006 Jan 1;107(1):265-76
pubmed: 16150940
Blood. 2001 May 15;97(10):3177-83
pubmed: 11342446
Viruses. 2016 Jun 16;8(6):
pubmed: 27322308
Nature. 2018 Aug;560(7719):494-498
pubmed: 30089906
J Exp Med. 1979 Aug 1;150(2):246-55
pubmed: 88499
Nat Immunol. 2003 Apr;4(4):337-42
pubmed: 12612581
Blood. 2014 Jun 19;123(25):3925-31
pubmed: 24735963
Science. 2003 Feb 14;299(5609):1057-61
pubmed: 12522256
PLoS Pathog. 2011 Feb 10;7(2):e1001274
pubmed: 21347344
Front Immunol. 2018 Jul 10;9:1444
pubmed: 30061879
Nat Biotechnol. 2020 Dec;38(12):1408-1414
pubmed: 32747759
Cancer Med. 2017 Jan;6(1):298-309
pubmed: 28035765
Clin Exp Immunol. 2019 Jul;197(1):14-23
pubmed: 30076771
Annu Rev Immunol. 2001;19:475-96
pubmed: 11244044
J Immunol. 2020 Feb 15;204(4):733-744
pubmed: 32015076
Annu Rev Immunol. 2018 Apr 26;36:43-71
pubmed: 29144838
Int Immunol. 2006 Feb;18(2):269-77
pubmed: 16361311
Cell Rep. 2019 Oct 15;29(3):724-735.e4
pubmed: 31618639
Blood. 2017 Nov 23;130(21):2326-2338
pubmed: 28978570
Nat Methods. 2017 Oct;14(10):979-982
pubmed: 28825705
Nat Immunol. 2003 Apr;4(4):330-6
pubmed: 12612578
Nat Rev Cancer. 2007 Apr;7(4):270-80
pubmed: 17384582
Nat Commun. 2017 May 10;8:15244
pubmed: 28489076
Blood. 2011 Aug 18;118(7):1865-76
pubmed: 21705495
Wellcome Open Res. 2017 Sep 22;2:87
pubmed: 29062917
J Exp Med. 1985 Dec 1;162(6):2169-74
pubmed: 2866223
Br J Haematol. 2004 Jul;126(1):81-4
pubmed: 15198736
Leuk Lymphoma. 2015 Jun;56(6):1806-12
pubmed: 25219595
Nat Commun. 2020 Apr 14;11(1):1801
pubmed: 32286271
Nat Commun. 2021 Aug 10;12(1):4821
pubmed: 34376672
J Immunol. 2006 Apr 15;176(8):4622-31
pubmed: 16585553
Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415-9
pubmed: 6261256
Proc Natl Acad Sci U S A. 2018 Feb 6;115(6):E1269-E1278
pubmed: 29358408
Blood. 2003 Apr 1;101(7):2704-10
pubmed: 12433692
Cancer Cell. 2012 Jan 17;21(1):121-35
pubmed: 22264793
J Immunol. 2006 Oct 15;177(8):5718-26
pubmed: 17015761
Nat Genet. 2015 Nov;47(11):1304-15
pubmed: 26437031
Proc Natl Acad Sci U S A. 2006 Jan 17;103(3):720-5
pubmed: 16407133
Sci Immunol. 2019 May 31;4(35):
pubmed: 31152091
J Biol Chem. 2003 Oct 31;278(44):43620-7
pubmed: 12937177
Int Immunol. 1995 Aug;7(8):1295-9
pubmed: 7495736
Nat Biotechnol. 2021 Aug;39(8):958-967
pubmed: 33649568
Nat Immunol. 2011 Aug 14;12(9):898-907
pubmed: 21841785
J Immunol. 1981 Apr;126(4):1393-7
pubmed: 6970774
Biochim Biophys Acta. 2016 Jun;1863(6 Pt A):1269-81
pubmed: 27033518
Immunity. 2009 Jun 19;30(6):899-911
pubmed: 19464196